With the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow or halt the progressive disease, the community is crying out for new drugs.
Acadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into its flagship Parkinson’s drug Nuplazid revealed no new risks – but documents h
AbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease and another $1.5 billion in potential fees.
Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.